Floatz logo

Cefepime

Poor Prognosis Metastatic Gestational Trophoblastic Tumor

Wake Forest University Health SciencesSmall moleculePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

6 Active assets in the Poor Prognosis Metastatic Gestational Trophoblastic Tumor cohort.

Asset / SponsorPhaseRating
Amifostine
Gynecologic Oncology Group
Phase 3B
FILGRASTIM
Fred Hutchinson Cancer Center
Phase 2B
IMMUNOGLOBULIN G1 (HUMAN-RAT MONOCLONAL CAMPATH-1H .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD52), DISULFIDE WITH HUMAN-RAT MONOCLONAL CAMPATH-1H LIGHT CHAIN, DIMER
Fred Hutchinson Cancer Center
Phase 2B
MOXIFLOXACIN
OHSU Knight Cancer Institute
Phase 3B
TACROLIMUS
Case Comprehensive Cancer Center
Phase 2B

View all 25 →

Same molecule, other indications

Cefepime is also rated in:

neutropeniaDormant
BB
Indicative ·
70 / 100
View asset →
Pediatric CancerDormant
B
Indicative ·
62 / 100
View asset →
Invasive Bacterial InfectionDormant
B
Indicative ·
62 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →